Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of COPD with symptoms over 1 year
FEV1/FVC \< 70% and FEV1 \>= 40 and \< =70 % of predicted post-bronchodilator
Ex-smokers for at least 12 months
You may not be if
Past history or current evidence of clinically significant heart disease
Current diagnosis of asthma
Worsening of COPD requiring hospitalisation and/or treatment with antibiotics and/or an increase in inhaled steroid dose and/or oral steroids within 4 weeks of study visit 1b